As of Apr 29
| +0.06 / +1.81%|
The 4 analysts offering 12-month price forecasts for AcelRx Pharmaceuticals Inc have a median target of 6.50, with a high estimate of 10.50 and a low estimate of 4.00. The median estimate represents a +92.31% increase from the last price of 3.38.
The current consensus among 5 polled investment analysts is to Buy stock in AcelRx Pharmaceuticals Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.